Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Gains from Investment Securities (2013 - 2026)

Scynexis' (SCYX) quarterly Gains from Investment Securities came in at -$14.2 million in Q2 2026, down 553.37% on a YoY basis from $3.1 million in Q2 2025, and down 369.61% quarter-over-quarter from $5.2 million in Q1 2026.

Analysis

Scynexis (SCYX) Gains from Investment Securities (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Gains from Investment Securities for 13 consecutive years, with -$14.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Gains from Investment Securities fell 553.37% year-over-year to -$14.2 million; the trailing twelve-month figure through Jun 2026 stood at -$9.6 million (up 36.69% YoY), and the FY2025 full-year result was -$5.8 million, up 58.01% from the prior year.
  • Gains from Investment Securities retreated to -$14.2 million in Q2 2026 per SCYX's latest filing, from $5.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $21.7 million in Q3 2022 and bottomed at -$14.2 million in Q2 2026.
  • Historically, Gains from Investment Securities has averaged -$1.8 million across 5 years, with a median of -$3.1 million in 2024.
  • The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities plunged 671.54% in 2022, then surged 316.08% in 2023.
  • Over 5 years, Gains from Investment Securities stood at -$9.1 million in 2022, then soared by 69.18% to -$2.8 million in 2023, then decreased by 14.71% to -$3.2 million in 2024, then surged by 59.53% to -$1.3 million in 2025, then tumbled by 988.62% to -$14.2 million in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods registered -$14.2 million, $5.2 million, and -$1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Scynexis 58.41 Mn -56.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -14.15 Mn
Mar 31, 2026 5.25 Mn
Dec 31, 2025 -1.30 Mn
Sep 30, 2025 640,000.00
Jun 30, 2025 -2.17 Mn
Mar 31, 2025 -2.93 Mn
Dec 31, 2024 -3.21 Mn
Sep 30, 2024 -6.80 Mn
Jun 30, 2024 5.80 Mn
Mar 31, 2024 -9.61 Mn
Dec 31, 2023 -2.80 Mn
Sep 30, 2023 -7.50 Mn
Jun 30, 2023 -8.21 Mn
Mar 31, 2023 21.67 Mn
Dec 31, 2022 -9.09 Mn
Sep 30, 2022 21.70 Mn
Jun 30, 2022 -9.70 Mn
Mar 31, 2022 -10.03 Mn
Sep 30, 2021 -18.81 Mn
Jun 30, 2021 -15.30 Mn